EUVIMEDEUVIMED entdecken
EditorialKommentar

miR ‐21p‐5p coordinates biological pathways to promote MASLD progression

Patricia Aspichueta iD, Mirjam B Zeisel iD

Liver International · 2023-11 · 43 (11) · 2343-2345

DOI: 10.1111/liv.15740 ↗

Kurz gefasst

Editorial in der Zeitschrift Liver International, online erschienen am 17.10.2023. Verfasst von Patricia Aspichueta und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, MicroRNAs. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

13 and patients might benefit from increasing it; however, in β - catenin-dependent​HCC,​where​tumours​are​addicted​to​fatty​acids​and​FAO​ is increased, 18 inhibition— instead of activation— of this metabolic process will be required. Rodrigues et al. 10 ​observed​that​lack​of​miR-​ 21-​5p​protects,​at​least​in​part,​from​MASH-​related​HCC.​However,​ using different preclinical models of HCC, Correia de Sousa et al. 19 demonstrated that miR-21 deletion promotes HCC initiation. Thus, even​though​another​variable​to​be​considered​for​MASLD​classifi - cation​and​treatment​might​be​the​levels​of​miRNAs​which​are​in - volved in the progression of the disease, the potential benefits of miR- 21-5p inhibition in HCC need to be further investigated.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsMicroRNAsHumansCell ProliferationCell Line, TumorDisease ProgressionGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

PPARαhepatocellular carcinoma (HCC)metabolic dysfunction-associated steatohepatitis (MASH)metabolic dysfunction-associated steatotic liver disease (MASLD)miR-21-5p

Substanzen

MicroRNAs

Autor:innen und Institutionen

  • Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain.
  • Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.
  • Cancer Research Center of Lyon (CRCL), UMR Inserm 1052 CNRS 5286 Mixte CLB, Université de Lyon (UCBL), Lyon, France.

ORCID-Profile: Patricia Aspichueta, Mirjam B Zeisel

Zitieren

APA

Aspichueta, P., & Zeisel, M. B. (2023). miR ‐21p‐5p coordinates biological pathways to promote MASLD progression. Liver International, 43(11), 2343-2345. https://doi.org/10.1111/liv.15740

Vancouver

Aspichueta P, Zeisel MB. miR ‐21p‐5p coordinates biological pathways to promote MASLD progression. Liver International. 2023;43(11):2343-2345. doi:10.1111/liv.15740

BibTeX
@article{Aspichueta2023,
  author = {Aspichueta, Patricia and Zeisel, Mirjam B},
  title = {miR ‐21p‐5p coordinates biological pathways to promote MASLD progression},
  journal = {Liver International},
  year = {2023},
  volume = {43},
  number = {11},
  pages = {2343--2345},
  doi = {10.1111/liv.15740}
}
Kostenlos starten →